Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

isunakinra

A recombinant protein resembling interleukin-1 (IL-1) receptor antagonist (IL-1Ra), with potential anti-inflammatory, immunomodulatory and antineoplastic activities. Upon administration, isunakinra targets and binds to the IL-1 receptor type 1 (IL-1-R1; IL-1R1; IL1R1), thereby blocking the binding of IL-1 alpha and beta to and activation of its receptor. Blockade of IL-1 activity and IL-1R1-mediated signaling inhibits the release of other pro-inflammatory mediators and may suppress inflammation and immunological responses. This may also abrogate the inflammatory and the immunosuppressive nature of the tumor microenvironment (TME), and may inhibit tumor growth, invasion, metastasis, and angiogenesis. IL-1/IL-1R1 signaling plays a key role in inflammation, which is present in various disease states including certain types of cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search